Research Trials

POLO

A randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2mutation (gBRCAm) who have not progressed following first-line chemotherapy.

 

APACT

A phase III randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with surgically resected ductal pancreatic adenocarcinoma (PDA).

 

IMPaCT

Individualised Molecular Pancreatic Cancer Therapy (IMPaCT) is an Australian clinical trial looking at personalising the treatment of patients with metastatic pancreatic cancer. New protocol, standard gem or gem/abraxane followed by targeted therapy. A phase II trial assessing feasibility of personalised treatment based on tumour molecular signature in patients with recurrent or metastatic pancreatic cancer. Genomic sequencing of  these loci HER2, BRCA1/BRCA2 or PALB2 and Anti EGFR.

 

Janus 1

A randomised double blind phase III study of the JAK ½ inhibitor ruxolitinib or placebo in combination with capecitabine in subjects with advanced or metastatic adenocarcinoma of the pancreas who have failed or are intolerant to first line chemotherapy